Guillain-Barré syndrome and its treatment

Expert Review of Neurotherapeutics

Volumn 6, Issue 10, 2006, Pages 1569-1574

  Douglas, Michael R ^a   Winer, John B ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Antiganglioside antibodies; Campylobacter jejuni; Guillain Barr syndrome; Intravenous immunoglobulin treatment; Plasma exchange

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ARTIFICIAL TEAR; BETA INTERFERON; COMPLEMENT INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; HEPARIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LAXATIVE; OPIATE; PROTEIN INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTIFICIAL VENTILATION; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DIAGNOSTIC ACCURACY; FECES IMPACTION; FILTRATION; GRAM NEGATIVE INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOADSORPTION; INCIDENCE; KERATITIS; LIMB MOVEMENT; LUNG EMBOLISM; META ANALYSIS; NEUROLOGIC EXAMINATION; NONHUMAN; NUTRITIONAL ASSESSMENT; PHYSIOTHERAPY; PLASMAPHERESIS; RADICULAR PAIN; REVIEW; SERODIAGNOSIS; SYSTEMATIC REVIEW; TENDON CONTRACTURE; UNSPECIFIED SIDE EFFECT;

GUILLAIN-BARRE SYNDROME; HUMANS;

EID: 33750624589     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.10.1569     Document Type: Review

References (76)

1. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les characteres clinique et graphique des reflexes tendinaux. Bull. Soc. Med. Hop. 40, 1462-1470 (1916).
2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27(Suppl.), S21-S24 (1990).
3. Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology 61(11), 1507-1512 (2003).
4. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch. Neurol. 49(6), 612-616 (1992).
5. Ad Hoc SotAAoNATF. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 41, 617-618 (1991).
6. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 48(3), 173-215 (1969).
7. Prineas JW. Acute idiopathic polyneuritis. An electron microscope study. Lab. Invest. 26(2), 133-147 (1972).
8. Feasby TE, Gilbert JJ, Brown WF et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 109(Pt 6), 1115-1126 (1986).
9. McKhann GM, Cornblath DR, Ho T et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338(8767), 593-597 (1991). Description of acute motor axonal neuropathy (AMAN).
10. McKhann GM, Cornblath DR, Griffin JW et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 33(4), 333-342 (1993).
11. Griffin JW, Li CY, Ho TW et al. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118(Pt 3), 577-595 (1995).
12. Griffin JW, Li CY, Ho TW et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann. Neurol. 39(1), 17-28 (1996).
13. Hadden RD, Cornblath DR, Hughes RA et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann. Neurol. 44(5), 780-788 (1998).
14. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann. Neurol. 46(5), 701-707 (1999).
15. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol. 48(4), 624-631 (2000).
16. Fisher C. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Eng. J. Med. 225, 57-75 (1956). First description of Miller Fisher syndrome.
17. Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch. Neurol. 51(7), 671-675 (1994).
18. Susuki K, Atsumi M, Koga M, Hirata K, Yuki N. Acute facial diplegia and hyperreflexia: A Guillain-Barré syndrome variant. Neurology 62(5), 825-827 (2004).
19. Kuwabara S, Nakata M, Sung JY et al. Hyperreflexia in axonal Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Neurol. Sci. 199(1-2), 89-92 (2002).
20. Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N. Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J. Neurol. Neurosurg. Psychiatr. 67(2), 180-184 (1999).
21. Podnar S, Vodusek DB. Hyperreflexia in a patient with motor axonal Guillain-Barré syndrome. Eur. J. Neurol. 7(6), 727-730 (2000).
22. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J. Neurol. Neurosurg. Psychiatr. 51(5), 605-612 (1988).
23. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J. Infect. Dis. 176(Suppl. 2), S92-S98 (1997).
24. Blaser MJ, Olivares A, Taylor DN, Cornblath DR, McKhann GM. Campylobacter serology in patients with Chinese paralytic syndrome. Lancet 338(8762), 308 (1991).
25. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J. Neuroimmunol. 100(1-2), 74-97 (1999).
26. Winer JB. Guillain Barré syndrome. Mol. Pathol. 54(6), 381-385 (2001).
27. Meulstee J, van der Meche FG. Electrodiagnostic studies in the Dutch multicentre Guillain-Barré study: a review. J. Peripher. Nerv. Syst. 2(2), 143-150 (1997).
28. Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29(4), 565-574 (2004).
29. McLeod JG. Electrophysiological studies in the Guillain-Barré syndrome. Ann. Neurol. 9(Suppl.), 20-27 (1981).
30. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 12(6), 435-451 (1989).
31. Olney RK, Aminoff MJ. Electrodiagnostic features of the Guillain-Barré syndrome: the relative sensitivity of different techniques. Neurology 40(3 Pt 1), 471-475 (1990).
32. Murray NM, Wade DT. The sural sensory action potential in Guillain-Barré syndrome. Muscle Nerve 3(5), 444 (1980).
33. Ledeen RW, Wu G. Ganglioside function in calcium homeostasis and signaling. Neurochem. Res. 27(7-8), 637-647 (2002).
34. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125(Pt 12), 2591-2625 (2002).
35. van Sorge NM, van der Pol WL, Jansen MD, van den Berg LH. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. Autoimmun. Rev. 3(2), 61-68 (2004).
36. Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J. Neurol. Neurosurg. Psychiatr. 66(3), 376-379 (1999).
37. Sumner A, Said G, Idy I, Metral S. Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat (author's transl.). Rev. Neurol. (Paris) 138(1), 17-24 (1982).
38. Harrison BM, Hansen LA, Pollard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann. Neurol. 15(2), 163-170 (1984).
39. Saida T, Saida K, Lisak RP, Brown MJ, Silberberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann. Neurol. 11(1), 69-75 (1982).
40. Winer JB, Gray IA, Gregson NA et al. A prospective study of acute idiopathic neuropathy. III. Immunological studies. J. Neurol. Neurosurg. Psychiatr. 51(5), 619-625 (1988).
41. Oomes PG, van der Meche FG, Markus-Silvis L, Meulstee J, Kleyweg RP. In vivo effects of sera from Guillain-Barré subgroups: an electrophysiological and histological study on rat nerves. Muscle Nerve 14(10), 1013-1020 (1991).
42. Harvey GK, Toyka KV, Zielasek J, Kiefer R, Simonis C, Hartung HP. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 18(4), 388-394 (1995).
43. Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain- Barré syndrome: a macro-patch-clamp study. Ann. Neurol. 44(6), 913-922 (1998). Of interest.
44. Buchwald B, de Baets M, Luijckx GJ, Toyka KV. Neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child. Neurology 53(6), 1246-1253 (1999).
45. Hirota N, Kaji R, Bostock H et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 120(Pt 12), 2159-2169 (1997).
46. Paparounas K, O'Hanlon GM, O'Leary CP, Rowan EG, Willison HJ. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 122(Pt 5), 807-816 (1999).
47. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann. Neurol. 39(4), 424-431 (1996).
48. Yuki N, Yamada M, Koga M et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 49(6), 712-720 (2001). Pathogenesis of AMAN.
49. O'Hanlon GM, Paterson GJ, Veitch J, Wilson G, Willison HJ. Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol. 95(6), 605-616 (1998).
50. Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37(4), 436-442 (1995).
51. Westland KW, Pollard JD, Sander S, Bonner JG, Linington C, McLeod JG. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain 122(Pt 7), 1283-1291 (1999).
52. Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ, Pierce SK. Location is everything: lipid rafts and immune cell signaling. Ann. Rev. Immunol. 21, 457-481 (2003).
53. van Sorge NM, van den Berg LH, Geleijns K et al. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fc. receptors. Ann. Neurol. 53(5), 570-579 (2003).
54. O'Hanlon GM, Plomp JJ, Chakrabarti M, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124(Pt 5), 893-906 (2001).
55. Plomp JJ, Molenaar PC, O'Hanlon GM et al. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann. Neurol. 45(2), 189-199 (1999). Published erratum appears in Ann. Neurol. 45(6), 823 (1999).
56. Pritchard J, Gray IA, Idrissova ZR et al. A randomized controlled trial of recombinant interferon-β 1a in Guillain-Barré syndrome. Neurology 61(9), 1282-1284 (2003).
57. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Gullian-Barré syndrome. Cochrane Database Syst. Rev. 2, CD001446 (2006).
58. Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 26(3), 205-212 (1976).
59. Shukla SK, Agarwal R, Gupta OP, Pande G, Singh M. Double blind controlled trial of prednisolone in Guillain-Barré syndrome - a clinical study. Clinician (India) 52(5), 128-134 (1988).
60. Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J. Assoc. Physicians India 44(1), 22-24 (1996).
61. Bansal BC, Sood AK, Gupta AK, Yadav P. Role of steroids in the treatment of Guillain Barré syndrome - a controlled trial. Neurology (India) 34(5), 329-335 (1986).
62. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 2(8093), 750-753 (1978).
63. Garcia AC, Vidal BE, Rebolledo FA, Texeira F, Ordaz FA, Futran YJ. Treatment of the acute phase of Guillain-Barré-Strohl syndrome with megadoses of methylprednisolone. Rev. Invest. Clin. (Mexico City) 37, 119-124 (1985).
64. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341(8845), 586-590 (1993).
65. Van Koningsveld R, Schmitz PIM, Van der Meché FGA, Visser VH, Meulstee J, Van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome. Randomised trial. Lancet 363(9404), 192-196 (2004).
66. Farkkila M, Kinnunen E, Haapanen E, Iivanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 37(5), 837-840 (1987).
67. Greenwood R, Newsom-Davis J, Hughes RA et al. British multicentre trial of plasma exchange in acute inflammatory polyradiculoneuropathy (AIP). Prog. Clin. Biol. Res. 106, 189-196 (1982).
68. Anonymous. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 35(8), 1096-1104 (1985).
69. Osterman PO, Fagius J, Lundemo G et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2(8415), 1296-1299 (1984).
70. Anonymous. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann. Neurol. 22(6), 753-761 (1987).
71. Anonymous. Appropriate number of plasma exchanges in Guillain- Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann. Neurol. 41(3), 298-306 (1997).
72. Wollinsky K, Hulser P, Brinkmeier H et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 57(5), 774-780 (2001).
73. Hughes RAC, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Review: Oxford: Update Software Edition (2002).
74. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in South East England. J. Neurol. Neurosurg. Psychiatr. 64(1), 74-77 (1998).
75. Merkies I, Schmitz P, Samijn J, van der Meche FG, van Doom PE. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53(8), 1648-1654 (1999).
76. Willison HJ, Townson K, Veitch J et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127(Pt 3), 680-691 (2004).